Monday, October 2, 2023
| Characteristic | Likelihood ratio test† | aRR (95% CI) | p-value | |
|---|---|---|---|---|
| Chi-square | p-value | |||
| Vascular access type§ | ||||
| Central venous catheter | 2,090.2 | <0.001 | 6.2 (5.7–6.7) | <0.001 |
| Graft or other | 2.2 (2.0–2.4) | <0.001 | ||
| Fistula | Ref | — | ||
| Location/Hospital affiliation¶ | ||||
| Hospital** | 113.0 | <0.001 | 1.5 (1.3–1.8) | <0.001 |
| Freestanding | Ref | — | ||
| Member of group or chain of dialysis centers¶ | ||||
| No | 111.7 | <0.001 | 1.4 (1.2–1.7) | <0.001 |
| Yes | Ref | — | ||
| Written antibiotic use policy¶ | ||||
| No | 35.1 | <0.001 | 1.3 (1.1–1.4) | <0.001 |
| Yes | Ref | — | ||
| Quartile of % of persons aged ≥65 yrs†† | ||||
| Quartile 4: 75–100 (highest) | 54.3 | <0.001 | 1.4 (1.2–1.6) | <0.001 |
| Quartile 3: 50–74 | 1.3 (1.2–1.5) | <0.001 | ||
| Quartile 2: 25–49 | 1.3 (1.2–1.4) | <0.001 | ||
| Quartile 1: 0–24 (lowest) | Ref | — | ||
Table 1. Independent factors associated with dialysis-associated Staphylococcus aureus bloodstream infection incidence* — National Healthcare Safety Network, United States, 2020
Abbreviations: aRR = adjusted rate ratio; ATSDR = Agency for Toxic Substances and Disease Registry; NHSN = National Healthcare Safety Network; Ref = referent group; SVI = Social Vulnerability Index.
* Negative binomial regression was used to fit this multivariate model.
† Likelihood ratio test evaluates whether a factor is statistically significantly associated with Staphylococcus aureus bloodstream infection incidence. Additionally, Akaike and Bayesian information criteria and Wald and likelihood ratio chi-square tests were used to evaluate model fit. The best candidate model was validated using bootstrap resampling methods and independently assessed by two separate analysts.
§ Source of data was NHSN event surveillance.
¶ Source of data was NHSN Outpatient Dialysis Center Practices Survey. https://www.cdc.gov/nhsn/forms/57.500_outpatientdialysissurv_blank.pdf
** Location could be a hospital or a freestanding location owned by a hospital.
†† Source of data was CDC/ATSDR SVI.
| Characteristic | Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| No. of S. aureus bloodstream infections | No. of patient-years | Unadjusted rate† | aRR§ (95% CI) | p-value | |
| Age groups, yrs¶ | |||||
| 18–49 | 736 | 11,848 | 6,212 | 1.7 (1.5–1.9) | <0.001 |
| 50–64 | 993 | 22,312 | 4,451 | 1.2 (1.1–1.4) | <0.001 |
| ≥65 | 1,071 | 31,758 | 3,372 | Ref | — |
| Sex | |||||
| Female | 1,112** | 28,239 | 3,938 | Ref | — |
| Male | 1,685 | 37,679 | 4,472 | 1.2 (1.1–1.4) | <0.001 |
| EIP site | |||||
| California | 822 | 23,478 | 3,501 | 1.1 (0.9–1.4) | 0.19 |
| Connecticut | 182 | 4,404 | 4,133 | 1.2 (1.0–1.5) | 0.12 |
| Georgia | 393 | 6,218 | 6,320 | 2.0 (1.6–2.5) | <0.001 |
| Maryland | 741 | 15,022 | 4,933 | 1.4 (1.1–1.7) | 0.003 |
| New York | 242 | 5,024 | 4,817 | 1.3 (1.0–1.6) | 0.05 |
| Tennessee | 183 | 4,190 | 4,368 | 1.2 (1.0–1.5) | 0.12 |
| Minnesota | 237 | 7,582 | 3,126 | Ref | — |
| Race and ethnicity†† | |||||
| Black, non-Hispanic | 1,509 | 31,762 | 4,751 | 1.1 (0.9–1.2) | 0.40 |
| Hispanic | 321 | 7,122 | 4,500 | 1.4 (1.2–1.7) | <0.001 |
| White, non-Hispanic | 687 | 17,764 | 3,866 | Ref | — |
| Other, non-Hispanic | 284 | 9,270 | 3,061 | 1.0 (0.8–1.2) | 0.92 |
| Vascular access types§§ | |||||
| Central venous catheter | 1,444 | 11,963 | 12,071 | 4.3 (3.9–4.8) | <0.001 |
| Fistula or graft | 1,303 | 48,631 | 2,679 | Ref | — |
| Total | 2,800 | 65,918 | 4,248 | — | — |
Table 2. Staphylococcus aureus bloodstream infections associated with hemodialysis — Emerging Infections Program,* United States, 2017–2020
Abbreviations: aRR = adjusted rate ratio; EIP = Emerging Infections Program; Ref = referent group; S. aureus = Staphylococcus aureus.
* EIP data for January 1, 2017–December 31, 2020.
† Per 100,000 hemodialysis person-years.
§ Adjusted for age, race and ethnicity, sex, vascular access type, and EIP site as appropriate.
¶ The median age of patients with hemodialysis S. aureus bacterial infection was 60 years (IQR = 49–70 years); the median age of those aged 18–49 years was 41 years.
** Sex was unknown for three patients.
†† Race and ethnicity were categorized as non-Hispanic Black or African American (Black), Hispanic or Latino (Hispanic), non-Hispanic White, and non-Hispanic other (includes patients with more than one race recorded). Race and ethnicity case counts are averaged over 10 imputations to account for missing values of race and ethnicity. The total sums to >2,800 because of rounding.
§§ Fifty-three cases had unknown vascular access type. The denominator includes 5,324 hemodialysis patient-years with unknown vascular access type.
Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.50 ABIM MOC points
Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)
This activity is intended for primary care clinicians, infectious disease specialists, nephrologists, and other healthcare professionals who treat and manage patients with end-stage kidney disease.
The goal of this activity is for learners to be better able to evaluate risk factors of hemodialysis-associated Staphylococcus aureus bloodstream infections in the setting of end-stage kidney disease.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-148-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit(s)™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 5/13/2023
Valid for credit through: 5/13/2024, 11:59 PM EST
processing....
Introduction: Racial and ethnic minorities are disproportionately affected by end-stage kidney disease (ESKD). ESKD patients on dialysis are at increased risk for Staphylococcus aureus bloodstream infections, but racial, ethnic, and socioeconomic disparities associated with this outcome are not well described.
Methods: Surveillance data from the 2020 National Healthcare Safety Network (NHSN) and the 2017–2020 Emerging Infections Program (EIP) were used to describe bloodstream infections among patients on hemodialysis (hemodialysis patients) and were linked to population-based data sources (CDC/Agency for Toxic Substances and Disease Registry [ATSDR] Social Vulnerability Index [SVI], United States Renal Data System [USRDS], and U.S. Census Bureau) to examine associations with race, ethnicity, and social determinants of health.
Results: In 2020, 4,840 dialysis facilities reported 14,822 bloodstream infections to NHSN; 34.2% were attributable to S. aureus. Among seven EIP sites, the S. aureus bloodstream infection rate during 2017–2020 was 100 times higher among hemodialysis patients (4,248 of 100,000 person-years) than among adults not on hemodialysis (42 of 100,000 person-years). Unadjusted S. aureus bloodstream infection rates were highest among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) hemodialysis patients. Vascular access via central venous catheter was strongly associated with S. aureus bloodstream infections (NHSN: adjusted rate ratio [aRR] = 6.2; 95% CI = 5.7–6.7 versus fistula; EIP: aRR = 4.3; 95% CI = 3.9–4.8 versus fistula or graft). Adjusting for EIP site of residence, sex, and vascular access type, S. aureus bloodstream infection risk in EIP was highest in Hispanic patients (aRR = 1.4; 95% CI = 1.2–1.7 versus non-Hispanic White [White] patients), and patients aged 18–49 years (aRR = 1.7; 95% CI = 1.5–1.9 versus patients aged ≥65 years). Areas with higher poverty levels, crowding, and lower education levels accounted for disproportionately higher proportions of hemodialysis-associated S. aureus bloodstream infections.
Conclusions and implications for public health practice: Disparities exist in hemodialysis-associated S. aureus infections. Health care providers and public health professionals should prioritize prevention and optimized treatment of ESKD, identify and address barriers to lower-risk vascular access placement, and implement established best practices to prevent bloodstream infections.
More than 800,000 persons in the United States live with ESKD, 70% of whom are treated with dialysis (89% hemodialysis and 11% peritoneal dialysis); 30% have a functioning kidney transplant[1]. Race, ethnicity, and social determinants of health* affect development of ESKD[1–4]. ESKD prevalence is fourfold higher among Black persons and more than twofold higher among Hispanic than among White persons[1], disparities which are thought to be attributable at least in part to underlying conditions such as hypertension and diabetes mellitus[1–3]. Furthermore, disparities in pre-ESKD nephrology care and receipt of ESKD therapies exist for these same groups, as well as those with lower income and insurance coverage[1,5–9]. Black persons constitute 33% of all U.S. patients receiving dialysis[1], but only 12% of the U.S. population[10].
Infections are a leading cause of morbidity and mortality in hemodialysis patients[1]. S. aureus is the most commonly isolated pathogen among bloodstream infections in hemodialysis patients reported to NHSN; 40% of those infections are methicillin resistant (MRSA)†[11]. Higher rates of invasive S. aureus infections have been observed in dialysis patients compared with nondialysis patients[12].
Type of hemodialysis access is a well-established risk factor for infections; risk is highest for central venous catheters (CVCs), lower for grafts, and lowest for fistulas[11]. Although elevated rates have been reported for both invasive MRSA infections among Black dialysis patients[13] and hospitalizations for dialysis-related infections among adult Black patients and older Hispanic patients (aged >60 years)[14], the association among hemodialysis-related infections, race and ethnicity, and social determinants of health is largely undescribed. To identify groups experiencing high numbers and risk of infections and to determine which preventive interventions should be prioritized, this study used a national facility-level reporting system and a laboratory- and population-based surveillance network to understand markers of disparities in the risk for S. aureus bloodstream infections in hemodialysis patients. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§
